×

CPRD StudyPrimary Care PASS Study

Abstract 274: Risk Factors of Major Bleeding in Patients Prescribed Rivaroxaban in Primary Care in England: Based on a Modified-Prescription Event Monitoring Study

Clinical trials and observational studies have reported bleeding risk in patients taking oral anticoagulants.

CPRD StudyPrimary Care PASS Study

Abstract 273: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Adverse Drug Reaction Reporting in the United Kingdom

Biological medical products (‘biologics’) are derived from living cells or organisms.

CPRD StudyPrimary Care PASS Study

Abstract 272: Changes in Evidence Supporting Post-Marketing Withdrawal of Marketing Authorisation in the EU

Market withdrawal of a product affects patients, healthcare professionals, regulators and manufacturers, therefore these decisions should be based on the most robust evidence available.

CPRD StudyPrimary Care PASS Study

Abstract 271: Impact analyses of EU pharmacovigilance interventions on public health burden

Adverse drug reactions (ADRs) account for 5% hospital admissions and 197,000 deaths each year, amounting to a societal cost of €79billion.

CPRD StudyPrimary Care PASS Study

Abstract 270: Distribution of CHA2DS2-VASc Scores in Patients with Atrial Fibrillation Treated with Rivaroxaban in Primary vs. Secondary Care Settings

Since its incorporation in the European Society of Cardiology guidelines in 2010, the CHA2DS2-VASc score is widely used to characterise the risk of stroke in patients (pts) with atrial fibrillation (AF).

CPRD StudyPrimary Care PASS Study

Abstract 269: Assessment of Start Dose in Patients Prescribed Rivaroxaban for Atrial Fibrillation with Chronic Kidney Disease-Results from the ROSE Study

Rivaroxaban is used to treat patients with non-valvular AF for the prevention of stroke and systemic embolism.

CPRD StudyPrimary Care PASS Study

Abstract 268: Characteristics of Patients Started on a Reduced Dose of Rivaroxaban for Atrial Fibrillation – Results from the ROSE Study

Rivaroxaban is used to treat a range of conditions, including prevention of stroke and systemic embolism in patients with AF.

CPRD StudyPrimary Care PASS Study

Abstract 267: Incidence Of Major And Clinically-Relevant Non-Major Bleeding In Patients Prescribed Rivaroxaban: Results From The ROSE Study

The ROSE (Rivaroxaban Observational Safety Evaluation) Specialist Cohort Event Monitoring (SCEM) study was conducted to monitor the safety and use of rivaroxaban for Stroke Prevention in patients (pts) with non-valvular AF (SPAF) and the prevention and/or treatment of Deep Vein Thrombosis and/or Pulmonary Embolism (DVT/PE) in the secondary care setting in England and Wales.

CPRD StudyPrimary Care PASS Study

Abstract 266: Multi-Level Modelling To Investigate Factors Impacting Prescribing Variability

Prescribing guidelines influence treatment choice based on patient and healthcare system factors.

CPRD StudyPrimary Care PASS Study

Abstract 265: Risk Of Major And Clinically Relevant Non-Major (CRNM) Bleeding In Patients Prescribed Rivaroxaban In Primary Care In England

Clinical trials and observational studies have reported bleeding risk in patients taking rivaroxaban.